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Outcome with lenalidomide plus dexamethasone followed by
early autologous stem cell transplantation in patients with
newly diagnosed multiple myeloma on the ECOG-ACRIN
E4A03 randomized clinical trial: long-term follow-up
N Biran1, S Jacobus2, DH Vesole3, NS Callander4, R Fonseca5, ME Williams6, R Abonour7, MS Katz8, SV Rajkumar9, PR Greipp10
and DS Siegel1
In Eastern Cooperative Oncology Group-ACRIN E4A03, on completion of four cycles of therapy, newly diagnosed multiple myeloma
patients had the option of proceeding to autologous peripheral blood stem cell transplant (ASCT) or continuing on their assigned
therapy lenalidomide plus low-dose dexamethasone (Ld) or lenalidomide plus high-dose dexamethasone (LD). This landmark
analysis compared the outcome of 431 patients surviving their ﬁrst four cycles of therapy pursuing early ASCT to those continuing
on their assigned therapy. Survival distributions were estimated using the Kaplan–Meier method and compared with log-rank test.
Ninety patients (21%) opted for early ASCT. The 1-, 2-, 3-, 4- and 5-year survival probability estimates were higher for early ASCT
versus no early ASCT at 99, 93, 91, 85 and 80% versus 94, 84, 75, 65 and 57%, respectively. The median overall survival (OS) in the
early versus no early ASCT group was not reached (NR) versus 5.78 years. In patients o65 years of age, median OS in the early
versus no early ASCT groups was NR in both, hazard ratio 0.79, 95% conﬁdence interval: (0.50, 0.25). In patients ⩾ 65 years of age,
median OS in the early versus no early ASCT was NR versus 5.11 years. ASCT dropped out of statistical signiﬁcance (P= 0.080).
Patients opting for ASCT after induction Ld/LD had a higher survival probability and improvement in OS regardless of
dexamethasone dose density.
Blood Cancer Journal (2016) 6, e466; doi:10.1038/bcj.2016.68; published online 2 September 2016
INTRODUCTION
High-dose chemotherapy and autologous peripheral blood stem
cell transplant (ASCT) were demonstrated in large, randomized
clinical trials, to improve progression-free survival (PFS) and overall
survival (OS) compared with standard chemotherapy in patients
with multiple myeloma (MM)1,2 Other randomized trials demon-
strated an improvement only in PFS with no signiﬁcant OS
beneﬁt.3,4 Because of the improved PFS resulting in prolonged
time off treatment without symptoms with improved quality of
life,3,5 ASCT following induction therapy has become an integral
part of treatment in patients with newly diagnosed MM (NDMM)
and continues to be the recommended treatment for transplant
eligible NDMM by the International Myeloma Working Group.6
Over the last decade, immunomodulatory agents (IMiDs) and
proteasome inhibitors (PIs) have led to a signiﬁcant improvement
in PFS, OS and response rates for patients with NDMM.7–9 Because
of the response rates, especially the depth of response to IMiDs
and PIs, the role of ASCT in the upfront setting has become more
controversial. Although most clinical practice guidelines recom-
mend early ASCT as the standard of care in transplant eligible
patients,10,11 some experts suggest that standard risk patients can
opt for delayed ASCT if stem cells can be cryopreserved.12 One
prospective trial randomized 253 patients with NDMM, aged 65
years or younger, to ASCT versus melphalan, prednisone and
lenalidomide consolidation after lenalidomide plus low-dose
dexamethasone (Ld) induction therapy and found that consolida-
tion with high-dose melphalan plus ASCT as compared with
melphalan, prednisone and lenalidomide consolidation signiﬁ-
cantly prolonged PFS and OS.13 Another study that compared
upfront ASCT versus chemotherapy with cyclophosphamide,
dexamethasone and lenalidomide with or without maintenance
showed a signiﬁcant PFS advantage with upfront ASCT.14
However, there continues to be an increasing trend towards
delaying ASCT. Hence, the timing of ASCT in the era of PIs and
IMiDs is a critically important question, especially in patients over
age 65 years. Preliminary results from the EMN02/H095 rando-
mized trial of 1308 newly diagnosed MM patients show a PFS
beneﬁt of upfront ASCT versus novel agent-based that was
maintained on multivariable Cox regression analysis.15
In the phase 3 clinical study Eastern Cooperative Oncology
Group (ECOG)-ACRIN E4A03, Ld was associated with better OS and
with lower toxicity compared with lenalidomide plus high-dose
dexamethasone (LD) in patients with NDMM.16 This study
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demonstrated the superiority of Ld over LD and led to the
widespread acceptance of Ld as a standard induction regimen.
More recently, the Frontline Investigation of Revlimid and
Dexamethasone versus Standard Thalidomide study has compared
Ld as continuous therapy versus Ld given for 18 cycles versus
melphalan plus prednisone plus thalidomide.17 Again, continuous
Ld, as had previously been described in EOCG E4A03 and
conﬁrmed in the Frontline Investigation of Revlimid and
Dexamethasone versus Standard Thalidomide trial, proved to be
superior and will likely lead to a more worldwide utilization of
continuous Ld as a standard induction regimen.
This analysis is the long-term follow-up to a prior post-hoc
retrospective landmark analysis (LM) comparing outcomes of early
versus no early ASCT. On completion of four cycles of therapy in the
ECOG-ACRIN E4A03 study, patients had the option of proceeding
with ASCT or continuing on the assigned therapy Ld or LD. In this
context, the primary objective was to evaluate the outcome of the
subpopulations of patients opting to pursue ASCT after four cycles
of therapy relative to the population not pursuing early ASCT and
either off study treatment or opting to continue with Ld or LD.
PATIENTS AND METHODS
Patients
Patients enrolled on the ECOG-ACRIN E4A03 randomized phase 3 clinical
trial, the results of which have been previously published,16 were included in
the current analysis. On E4A03, NDMM patients were randomized to LD
versus Ld. Patients on both arms received oral lenalidomide 25 mg orally
per day on days 1–21 of each 28-day cycle. Patients on LD received oral
dexamethasone 40 mg per day on days 1–4, 9–12 and 17–20 of each 28-day
cycle and patients on Ld received oral dexamethasone 40 mg per day on
days 1, 8, 15 and 22 of each 28-day cycle. Median duration of therapy was
4 months in the LD group and 6 months in the Ld group, with 14% of
patients in the LD group continuing on therapy 41 year versus 30% in Ld.
After the ﬁrst four cycles of therapy, patients could discontinue therapy,
some choosing to pursue stem cell transplantation (ASCT), or continue
therapy on study until disease progression. The decision for pursuing ASCT
may or may not have been made after four cycles. ASCT occurred within
6 months of discontinuation of therapy for patients in the early ASCT group.
Between November 2004 and April 2006, 445 patients were enrolled on
the E4A03 treatment trial from participating institutions. In the primary
study,16 there was evidence of an OS advantage on the Ld arm compared
with LD (96% versus 87%, Po0.001) at the ﬁrst pre-planned interim
analysis for response in March 2007, which occurred at a median follow-up
of 12.5 months and included 108 patients. Of note, OS was not a protocol-
speciﬁed endpoint. This prompted the Data Monitoring Committee to
release the study data and recommend cross-over of patients. At this time,
79 patients (18%) were still on treatment and all had passed the 4-cycle
primary endpoint. LD patients continuing therapy beyond 4 cycles were
advised to lower the dexamethasone dose by two-thirds from 12 to 4 days
per cycle. As such, longer-term OS analyses by treatment are confounded.
At 3 years, the OS curves by treatment cross, yielding a nonsigniﬁcant
P-value. The 3-year OS for both the Ld and LD arms was 75%.
Statistical design and analysis
Per protocol, patients received a minimum of four cycles of therapy parallel
to the primary endpoint of a 4-month response rate. The LM analysis that is
the subject of this study included 431 patients surviving the ﬁrst 4 cycles of
induction therapy. For this post-hoc analysis, early ASCT was deﬁned as ASCT
occurring within 6 months of discontinuation of study-mandated therapy. Of
note, patients in the ‘No Early SCT’ subgroup could have received ASCT at
some time. Data regarding subsequent therapies or PFS is not available.
This is a post-hoc, retrospective analysis of OS by early ASCT status
overall and within age subgroups dichotomized at 65 years.
The association of early ASCT status with OS was of primary interest but
additional endpoints evaluated were PFS, grade 3 or higher non-
hematological toxicity and best overall response rate (⩾partial response).
Survival distributions based on early ASCT status were estimated using the
Kaplan–Meier method and compared with the log-rank test. PFS was
deﬁned as the time from randomization to disease progression or death
due to any cause. Patients were censored at date of last disease evaluation
if they did not experience an event. Cox proportional hazards regression
was used to examine the relationship between baseline factors and
survival outcome in univariate and adjusted models, using stepwise
selection and adjusting for established prognostic factors. ASCT was
evaluated as a time-varying covariate.
The response criteria used were standard European Group for Blood and
Bone Marrow Transplant,18 except that responses were conﬁrmed 4 weeks
apart (instead of 6 weeks). Responses were classiﬁed according to the
International Myeloma Working Group response criteria.19 As the study did
not mandate bone marrow evaluation to conﬁrm complete response, a
category of immunoﬁxation-negative complete response was deﬁned as
conﬁrmed disappearance of the monoclonal protein in the serum and
urine by immunoﬁxation studies without the requirement for bone marrow
studies. Fisher’s exact test was used to compare response and toxicity rate.
A P-value of 0.05 was considered statistically signiﬁcant.
RESULTS
Number and characteristics of patients included in the LM analysis
Of the 431 patients including in the LM analysis, 183 (42.5%)
discontinued therapy after 4 cycles and 248 (57.5%) continued
their primary therapy beyond 4 cycles (Figure 1). Of the 183
patients who discontinued primary therapy, 93 (50.8%) did not
receive upfront ASCT and 90 (49%) opted for early ASCT. Of the
341 patients who did not pursue early ASCT, 93 patients went off
study therapy and 248 continued primary therapy. In the group of
patients who continued primary therapy, 60 eventually reported
receiving ASCT. Patients in this cohort had been randomized to
either Ld (n= 179, 52.5%) or LD (n = 162, 47.5%). Patients were
separated into subgroups based on age o65 years (n = 209,
48.5%) and age ⩾65 years (n= 222, 51.5%) for the LM analysis. Of
those who were o65 years old, 141 (67.5%) had no early ASCT
and 68 (32.5%) had early ASCT. Of those who were ⩾ 65 years old,
200 (90%) had no early ASCT and 22 (10%) had early ASCT.
At baseline (Table 1), early ASCT patients were younger (median
57.5 vs 66 year, Po0.001), more ﬁt (ECOG performance status 0,
45% vs 56%, P = 0.096) and with less aggressive disease (ISS Stage
3, 12% vs 28%, P = 0.002).
OS by early ASCT status
The 1-, 2-, 3-, 4- and 5-year survival probability estimates were
higher for early ASCT versus no ASCT at 99, 93, 91, 85 and 80%
versus 94, 84, 75, 65 and 57%. Survival probability differences
between patients in the early ASCT versus no early ASCT increased
Figure 1. LM analysis ﬂowchart. ASCT, autologous stem cell
transplant; Ld, lenalidomide plus low-dose dexamethasone; LD,
lenalidomide plus high-dose dexamethasone.
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with time. Differences between survival probability at 1, 2, 3, 4 and
5 years were 5, 9, 16, 21 and 23%, respectively. The median OS in
the early ASCT versus no early ASCT group was not reached
(NR) versus 5.78 years, respectively (P= 0.001; Figure 2a).
Survival hazard ratio was 0.55, 95% conﬁdence interval (95% CI):
(0.38–0.80).
In the subset of patients age o65 years, the difference in
survival probability between those who had early ASCT versus no
early ASCT at 1, 2, 3, 4 and 5 years was 5, 6, 12, 16 and 15%,
respectively. Thus, after 4 years there was no signiﬁcantly
continued difference in survival probability. In the subset of
patients aged 65 years or older, the difference in survival
probability between early ASCT and no early ASCT at 1, 2, 3, 4
and 5 years was 2, 9, 15, 25 and 30%, respectively. As such, the
difference in survival probability plateaued in younger patients
but increased each year in patients over 65 years.
In patients aged o65 years included in the LM analysis
(N= 209), median OS in patients who went on to early ASCT
(N= 68) versus no early ASCT (N= 141) was NR in both (P = 0.225;
Figure 2b). Survival hazard ratio was 0.79, 95% CI: (0.50–1.25). The
5-year survival probability of those who had early ASCT versus no
early ASCT was 79%, 95% CI: (70–89) versus 64%, 95% CI: (57–73).
In patients ⩾ 65 years of age included in the LM analysis
(N= 222), median OS in patients who had early ASCT (N= 22)
versus no early ASCT (N= 200) was NR versus 5.11 years (P = 0.011;
Figure 2c). Survival hazard ratio was 0.42, 95% CI: (0.21–0.86). The
5-year survival probability of those who had early ASCT versus no
early ASCT was 82%, 95% CI: (67–100) versus 52%, 95% CI: (45–59),
respectively.
OS by ASCT status and treatment arm
Median OS in all patients included in the LM analysis, who went
on to early ASCT for those who received LD (N= 50) versus Ld
(N= 40) was NR versus 7.24 years, respectively (P= 0.134). For
those who had no early ASCT, median OS for those who received
LD (N= 162) versus Ld (N= 179) was 5.63 versus 5.91 years,
respectively (P= 0.131). As stated above, cross-over occurred at
the ﬁrst pre-planned response interim analysis and, thus, makes it
impossible to make treatment comparisons.
Multivariable analysis
As the separation of the Kaplan–Meier curves does not account for
selection bias, early ASCT versus no early ASCT was evaluated in a
Cox proportional hazards multivariable regression model
adjusting for other known survival prognostic factors (Table 2).
ASCT, which was collected for only the ﬁrst 6 months post
treatment, was captured as a time-varying covariate. Other
variables included in the Cox proportional hazards regression
model included treatment (Ld vs LD), age (o65 vs ⩾ 65 years), ISS
Stage (I/II vs III) and ECOG performance status (0 vs 1/2). Age was
the only variable to emerge as statistically signiﬁcant (P = 0.04).
ASCT as a time-varying covariate fell out of signiﬁcance (P= 0.080).
Best four-cycle response
A potentially confounding factor in assessing the outcome of
patients going on to ASCT versus those who did not have an early
ASCT is the level of response at the completion of four cycles of
therapy. In the primary study the four-cycle overall response rate
(primary endpoint) was 73.7% (311/422) and in this LM data set
the rate was 74.4% (305/410). There was no statistically signiﬁcant
difference in the four-cycle overall response rate between patients
who chose early ASCT versus no early ASCT (Table 3).
Toxicity
Toxicity results over the four cycles of therapy could also inform
outcomes. Global grade 3–4 treatment-related non-hematological
toxicity is summarized in Table 4. In the primary study the 4-cycle
grade 3–4 treatment-related non-hematologic toxicity rate was
39.7% (176/443) and in this LM data set the rate was 40.5%
(174/430). Overall, there was a statistically signiﬁcant difference in
rates between early ASCT (28.9%) versus no early ASCT (43.5%),
P= 0.015. The difference widens in the older age group (18.2%)
but power is limited due to small sample size.
DISCUSSION
The ECOG-ACRIN E4A0316 demonstrated superior survival
probabilities for patients undergoing early ASCT relative to those
who did not have early ASCT (within 6 months of completing of
the fourth cycle of therapy). This was true at 1, 2, 3, 4 and 5 years
post study entry. The difference in survival probabilities between
early ASCT and no early ASCT increased with each year of follow-
up, with a doubling of the difference in the subset of patients
aged 65 years or older between years 3 and 5. However, caution
should be used in the interpretation of the subgroup analyses
given the lack of randomization, the lack of data on salvage
therapies, physician and patient bias, and the post-hoc nature of
this analysis. As an example, the cohort of patients aged ⩾ 65
Table 1. Baseline characteristics of patients included in the LM analysis for OS
Cohort Ageo65 years Age ⩾ 65 years Total
Variable No early SCT Early SCT No early SCT Early SCT No early SCT Early SCT P-value
Total 141 68 200 22 341 90
Age (year) Median (Q1,Q3) 57 (53,61) 54 (49,59) 72 (68,76) 67 (66,70) 66 (59,73) 58 (51,64) o0.001
Gender: male N (%) 79 (56.0) 36 (52.9) 110 (55.0) 16 (72.7) 189 (55.4) 52 (57.8) 0.721
Race: White N (%) 114 (80.9) 60 (88.2) 177 (88.5) 18 (81.8) 291 (85.3) 78 (86.7) 0.866
ISS: stage III N (%) 26 (19.3) 6 (9.5) 65 (34.8) 4 (19.1) 91 (28.3) 10 (11.9) 0.002
Unk 6 5 13 1 19 6
ECOG PS: 1–2 N (%) 75 (53.2) 29 (42.6) 112 (56.0) 11 (50.0) 187 (54.8) 40 (44.4) 0.096
Bone disease: present N (%) 89 (63.1) 49 (72.1) 112 (56.0) 16 (72.7) 201 (58.9) 65 (72.2) 0.021
FISH: high risk N (%) 7 (15.9) 4 (15.4) 8 (18.2) 2 (22.2) 15 (17.0) 6 (17.1) 1.000
Unk 97 42 156 13 253 55
β-2 Microglobulin (μg/ml) Median (Q1,Q3) 3.4 (2.4,4.6) 2.8 (2.3,3.8) 4.3 (2.7,6.7) 4.1 (3.5,5.2) 3.8 (2.6,5.7) 3.1 (2.4,4.3) 0.004
Unk 4 1 3 0 7 1
Hemoglobin (g/dL) Median (Q1,Q3) 10.9 (9.7,12.3) 11.8 (9.9,12.7) 10.9 (9.6,11.9) 11.3 (9.9,12.6) 10.9 (9.6,12.1) 11.7 (9.9,12.7) 0.017
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, ﬂuorescent in situ hybridization; LM, landmark; OS, overall survival;
SCT, stem cell transplantation.
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years, those in the early ASCT group compared with the no early
ASCT group were younger, more ﬁt (less ECOG performance status
1–2) and had less aggressive disease (less ISS stage 3). In
multivariable regression analysis attempting to correct for
established prognostic factors, ASCT as a time-varying covariate
only showed a trend toward improvement (P = 0.08).
The choice of early ASCT appeared to attenuate much of the
increased risk of death that occurred in patients assigned to the
LD arm of the trial. One potential explanation for the superiority of
outcome in those undergoing early ASCT is that those who went
on to early ASCT were destined to have a more favorable
prognosis due to factors such as age, baseline performance status,
improved response after four cycles of therapy (time point at
which treatment decision was made) or lower treatment-related
toxicity over the ﬁrst four cycles of therapy. This LM analysis
attempts to address these explanations, which would favorably
bias the early ASCT group.
By choosing this four-cycle LM at which to start the analysis, we
attempted to decrease the bias introduced by early deaths being
assigned to the non-ASCT arm. The LM analysis continued to
demonstrate that patients who went on to early ASCT after
induction lenalidomide and dexamethasone had a lower 1, 2, 3, 4
Figure 2. (a) Four-month LM analysis: OS by early ASCT status. (b) Four-month LM analysis: OS by early ASCT status in patients o65 years.
(c) Four-month LM analysis: OS by early ASCT status in patients ⩾ 65 years.
Table 2. Cox proportional hazards model for survival: multivariable
HR (95% CI) P-value
Adjusted Ld vs LD 1.06 (0.81–1.39) 0.673
SCT tvca 0.71 (048–1.04) 0.080
Age (o65 vs ⩾ 65 years) 0.66 (0.49–0.88) 0.004
ISS stage (I/II vs III) 0.67 (0.50–0.91) 0.010
ECOG PS (0 vs 1/2) 0.74 (0.56–0.97) 0.031
Abbreviations: ASCT, autologous peripheral blood stem cell transplant; CI,
conﬁdence interval; ECOG PS, Eastern Cooperative Oncology Group
performance status; HR, hazard ratio; Ld, low-dose dexamethasone; LD,
high-dose dexamethasone; SCT, stem cell transplantation; tvc, time-varying
covariate. aASCT and tvc. Bold value indicates statistical signiﬁcance.
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and 5-year mortality rate and corresponding improvement in OS
regardless of dexamethasone dose density (Ld or LD). This study is
subject to the usual limitations of a non-randomized study. The
relatively small numbers in overall and within each subset of age
cohort may have prevented the differences in survival to have
reached statistical signiﬁcance and may have been the reason for
ASCT to have fallen out of signiﬁcance in multivariable analysis.
The overwhelming majority of deaths related to progressive
MM occur beyond 1 year from the initiation of therapy. Thus,
1-year mortality was used as a surrogate for treatment-related
mortality. The presumption that treatment-related mortality
should be greater for older patients undergoing ASCT is addressed
by looking at the age465 years cohorts, where 1-year mortality is
similar between the early ASCT population and the no early ASCT
population. Although the number of older patients was not large,
there is no suggestion that older patients cannot do as well as
younger patients with proper patient selection. Transplant can be
effective and safely conducted in an older patient population and
the notion that older patients are not candidates for ASCT is not
supported by this limited data set.
In patients o65 years of age undergoing early ASCT, the
increased early risk of death associated with LD appears to be
dampened. This must be interpreted with caution, as it is possible
that patients who experienced signiﬁcant toxicity with LD were
unable to go on to ASCT and therefore were included in the no
early ASCT group.
Novel therapies have brought into question the role and, more
speciﬁcally, the timing of ASCT. Two older randomized studies
compared outcomes with early versus delayed transplant, both
completed before the incorporation of IMiD- or PI-based agents
into treatment algorithms. Fermand et al.3 showed an improve-
ment in event-free survival and improvement in quality of life in
terms of time without symptoms, treatment or treatment toxicity
in patients transplanted early, although there was no OS beneﬁt.
Similarly, Barlogie et al.20 compared high-dose therapy with
melphalan 140 mg/m2 and total body irradiation 12 cGy to
maintenance with vincristine, carmustine, melphalan, cyclopho-
sphamide and prednisone. On disease progression, the patients in
the vincristine, carmustine, melphalan, cyclophosphamide and
prednisone arm were to receive ASCT. There was no difference in
response rate, PFS or OS between arms, possibly due to an inferior
transplant preparative regimen. One trial has evaluated the role of
ASCT versus no transplant with the use of lenalidomide as part of
therapy. After induction with RD for 4 cycles, 273 patients o65
years of age with newly diagnosed MM were randomized to either
consolidation of melphalan, prednisone and lenalidomide for 6
cycles or to tandem ASCT.13 ASCT was to be performed in the non-
transplant arm at time of disease progression. With a median
follow-up of 51.2 months, both PFS and 4-year OS were
signiﬁcantly longer in the ASCT arm. Of those randomized to
melphalan, prednisone and lenalidomide, only 63% received the
planned ASCT at ﬁrst relapse, which may have led to the
signiﬁcant difference in OS. Gay et al.14 randomized 389 newly
diagnosed transplant-eligible MM patients to ASCT versus
cyclophosphamide-dex-lenalidomide chemotherapy after induc-
tion. PFS during consolidation was signiﬁcantly shorter with
chemotherapy plus lenalidomide compared with ASCT (median
28.6 versus 43.3 months, Po0.0001).14
Prospective, randomized clinical trials evaluating the outcomes
of early versus delayed ASCT in the era of IMiD and PI-based
therapies are ongoing (IFM-DFCI 2009 study NCT01208662 and
the European Intergroup Trial). The IFM/DFCI 2009/CTN 1304
parallel phase 3 study randomized newly diagnosed MM patients
to induction therapy with bortezomib, lenalidomide and dex-
amethasone (VRD) × 3 cycles and stem cell mobiliziation followed
by either ASCT and two cycles of RVD consolidation or ﬁve cycles
of RVD consolidation with lenalidomide maintenance for 1 year in
both arms. Results from a pre-speciﬁed interim analysis with a
median follow-up of 39 months showed an improvement in 3-year
PFS with ASCT versus RVD (61% versus 48%, respectively,
Po0.0002) and was uniform across all subgroups.21 The 3-year
post-randomization OS rate was extremely high (88%) and similar
between the two study groups. Further results of this trial and
other large prospective studies are needed to assess the role and
timing of ASCT.
In conclusion, the ECOG-ACRIN E4A03 demonstrated superior
survival probabilities for patients undergoing early ASCT relative
to those who did not have early ASCT. This was true in patients of
all age subgroups and maintained signiﬁcance in patients ⩾ 65
years, although in multivariable analysis adjusting for the
differences in cohorts as a result of subgroup analysis ASCT fell
out of signiﬁcance. The notion that the superior outcome for
patients undergoing early ASCT is due to the differences in age
between the two populations is not supported by this data.
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Table 4. Global grade 3–4 treatment-related non-hematological toxicity
No early SCT % (freq/n) Early SCT % (freq/n) Absolute difference Fisher’s exact P-value
Overall 43.5% (148/340) 28.9% (26/90) 14.6% 0.015
Ageo65 years 34.0% (48/141) 27.9% (19/68) 6.1% 0.431
Age ⩾ 65 years 50.0% (100/200) 31.8% (7/22) 18.2% 0.120
Abbreviations: CI, conﬁdence interval; SCT, stem cell transplant.
Table 3. Best response ⩾ PR at 4 months (primary endpoint)
No early SCT% (freq/n) Early SCT% (freq/n) Absolute difference Odds ratio (95% CI) Fisher’s exact P-value
Overall 75.4% (242/321) 70.8% (63/89) 4.6% 1.26 (0.75, 2.13) 0.411
Ageo65 years 75.7% (103/136) 70.6% (48/68) 5.1% 1.30 (0.68, 2.50) 0.499
Age ⩾ 65 years 75.1% (139/185) 71.4% (15/21) 3.7% 1.21 (0.44, 3.30) 0.791
Abbreviations: CI, conﬁdence interval; PR, partial remission; SCT, stem cell transplant.
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